DE122005000033I2 - Kalzium-Receptor aktive Verbindungen - Google Patents

Kalzium-Receptor aktive Verbindungen

Info

Publication number
DE122005000033I2
DE122005000033I2 DE1995633948 DE69533948C DE122005000033I2 DE 122005000033 I2 DE122005000033 I2 DE 122005000033I2 DE 1995633948 DE1995633948 DE 1995633948 DE 69533948 C DE69533948 C DE 69533948C DE 122005000033 I2 DE122005000033 I2 DE 122005000033I2
Authority
DE
Germany
Prior art keywords
phenyl
substits
substd
opt
naphthyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE1995633948
Other languages
English (en)
Other versions
DE69533948T2 (de
DE69533948D1 (de
Inventor
Bradford C Wagenen
Manuel F Balandrin
Scott T Moe
Eric G Delmar
Edward F Nemeth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire NPS Pharmaceuticals Inc
Original Assignee
NPS Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23390556&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122005000033(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US1994/012117 external-priority patent/WO1995011221A1/en
Priority claimed from US08/353,784 external-priority patent/US6011068A/en
Application filed by NPS Pharmaceuticals Inc filed Critical NPS Pharmaceuticals Inc
Publication of DE122005000033I2 publication Critical patent/DE122005000033I2/de
Active legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/28—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by unsaturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
DE1995633948 1994-10-21 1995-10-23 Kalzium-Receptor aktive Verbindungen Active DE122005000033I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1994/012117 WO1995011221A1 (en) 1991-08-23 1994-10-21 Calcium receptor-active arylalkyl amines
US08/353,784 US6011068A (en) 1991-08-23 1994-12-08 Calcium receptor-active molecules

Publications (1)

Publication Number Publication Date
DE122005000033I2 true DE122005000033I2 (de) 2006-11-23

Family

ID=23390556

Family Applications (4)

Application Number Title Priority Date Filing Date
DE69535461T Expired - Lifetime DE69535461T2 (de) 1994-10-21 1995-10-23 Kalzium-rezeptor aktive verbindungen
DE69533948T Expired - Lifetime DE69533948T2 (de) 1994-10-21 1995-10-23 Kalzium-Rezeptor aktive Verbindungen
DE200512000033 Pending DE122005000033I1 (de) 1994-10-21 1995-10-23 Kalzium-Rezeptor aktive Verbindungen.
DE1995633948 Active DE122005000033I2 (de) 1994-10-21 1995-10-23 Kalzium-Receptor aktive Verbindungen

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DE69535461T Expired - Lifetime DE69535461T2 (de) 1994-10-21 1995-10-23 Kalzium-rezeptor aktive verbindungen
DE69533948T Expired - Lifetime DE69533948T2 (de) 1994-10-21 1995-10-23 Kalzium-Rezeptor aktive Verbindungen
DE200512000033 Pending DE122005000033I1 (de) 1994-10-21 1995-10-23 Kalzium-Rezeptor aktive Verbindungen.

Country Status (25)

Country Link
US (1) US6211244B1 (de)
EP (4) EP1275635A1 (de)
JP (3) JP2882882B2 (de)
KR (2) KR100293621B1 (de)
CN (2) CN1147459C (de)
AT (2) ATE359259T1 (de)
AU (1) AU709303B2 (de)
BR (1) BRPI9509411B8 (de)
CA (1) CA2202879C (de)
CZ (2) CZ290670B6 (de)
DE (4) DE69535461T2 (de)
DK (1) DK1203761T3 (de)
ES (2) ES2234768T3 (de)
FR (1) FR05C0029I2 (de)
HK (4) HK1002454A1 (de)
HU (2) HU228150B1 (de)
LU (1) LU91182I2 (de)
NL (1) NL300199I2 (de)
NZ (1) NZ297157A (de)
PL (1) PL183499B1 (de)
PT (1) PT1203761E (de)
RU (1) RU2195446C2 (de)
TW (2) TW200402407A (de)
UA (1) UA55374C2 (de)
WO (1) WO1996012697A2 (de)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
EP1275635A1 (de) * 1994-10-21 2003-01-15 Nps Pharmaceuticals, Inc. Kalzium-Rezeptor aktive Verbindungen
WO1997005252A2 (en) * 1995-07-26 1997-02-13 Nps Pharmaceuticals, Inc. Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
ES2326004T3 (es) * 1996-05-01 2009-09-28 Nps Pharmaceuticals, Inc. Compuestos activos de receptor de ion inorganico.
EP1258471B1 (de) * 1996-05-01 2007-01-24 Nps Pharmaceuticals, Inc. Verbindungen, die auf anorganische Ionen-Rezeptoren wirken
EP1770083B1 (de) * 1996-05-01 2009-04-29 Nps Pharmaceuticals, Inc. Inorganische am Ionen-Rezeptor aktive Verbindungen
JP4331264B2 (ja) 1996-07-08 2009-09-16 協和発酵キリン株式会社 カルシウムレセプター活性化合物
US6210964B1 (en) * 1997-08-18 2001-04-03 The Brigham And Women's Hospital, Inc. Avian extracellular calcium-sensing receptor
AU760889B2 (en) 1998-10-14 2003-05-22 Ortho-Mcneil Pharmaceutical, Inc. 1,2-disubstituted cyclopropanes
US20040214889A1 (en) * 1999-07-31 2004-10-28 Smithkline Beecham Corporation Calcilytic compounds
EP1074539B1 (de) * 1999-08-04 2007-10-17 Sumitomo Chemical Company, Limited Verfahren zur Herstellung von optisch aktiver 3,3,3-Trifluor-2-hydroxy-2-methylpropionsäure und deren Salze
JP4595178B2 (ja) * 1999-08-04 2010-12-08 住友化学株式会社 アミン化合物、中間体、製造法および光学分割剤
US6797842B2 (en) * 2000-05-11 2004-09-28 Central Glass Company, Limited Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same
FR2809396B1 (fr) * 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
AR038658A1 (es) * 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US6849761B2 (en) 2002-09-05 2005-02-01 Wyeth Substituted naphthoic acid derivatives useful in the treatment of insulin resistance and hyperglycemia
GB0230015D0 (en) * 2002-12-23 2003-01-29 Novartis Ag Organic compounds
US7105537B2 (en) * 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
US7205322B2 (en) * 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
US7265145B2 (en) * 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
FR2855754B1 (fr) * 2003-06-05 2005-07-08 Oreal Compsition, notamment cosmetique, comprenant une amine carbonylee
ES2655435T3 (es) * 2003-09-12 2018-02-20 Amgen Inc. Formulación de disolución rápida de cinacalcet
US20050186658A1 (en) * 2003-10-17 2005-08-25 Nps Pharmaceuticals, Inc. Chimeric metabotropic glutamate receptors and uses thereof
JP4629036B2 (ja) 2004-05-28 2011-02-09 田辺三菱製薬株式会社 アリールアルキルアミン化合物及びその製法
US20050288377A1 (en) * 2004-06-14 2005-12-29 Cantor Thomas L Use of calcimimetic as an adynamic bone disease related treatment
JP2008506746A (ja) * 2004-07-22 2008-03-06 ディーエスエム アイピー アセッツ ビー．ブイ． ジアステレオマーに富んだ化合物の調製方法
US7361789B1 (en) 2004-07-28 2008-04-22 Amgen Inc. Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis
US20060276534A1 (en) * 2005-03-17 2006-12-07 Amgen Inc. Methods of decreasing calcification
FR2885129B1 (fr) * 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
WO2006125026A2 (en) * 2005-05-16 2006-11-23 Teva Pharmaceutical Industries, Ltd. Process for preparing cinacalcet hydrochloride
ES2334260T3 (es) * 2005-05-23 2010-03-08 Teva Pharmaceutical Industries Ltd. Procedimientos para la preparacion de la forma i cristalina de clorhidrato de cinacalcet.
MX2007000982A (es) * 2005-05-23 2007-04-16 Teva Pharma Clorhidrato de cinacalcet amorfo y preparacion del mismo.
US8486381B2 (en) 2005-09-02 2013-07-16 Amgen Inc. Methods of modulating intestinal fluid balance
US7595161B2 (en) 2005-11-10 2009-09-29 Hansjoerg Martin Rothe Efficacy of calcimimetic agents
US7563930B2 (en) * 2005-11-22 2009-07-21 Teva Pharmaceutical Industries Ltd Crystal forms of Cinacalcet HCI and processes for their preparation
ES2335360T3 (es) 2005-11-25 2010-03-25 Galapagos Sas Derivados de urea utiles como moduladores de los receptores de calcio.
US20070129444A1 (en) * 2005-12-06 2007-06-07 Mallinckrodt Inc. Novel weight reduction composition and uses thereof
EP3095447B1 (de) 2006-02-03 2021-11-24 OPKO Renal, LLC Behandlung von vitamin-d-insuffizienz und -mangel mit 25-hydroxyvitamin d2 und 25-hydroxyvitamin d3
AU2007230724B2 (en) 2006-03-23 2014-01-30 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
KR20080110681A (ko) * 2006-04-20 2008-12-18 암겐 인코포레이티드 안정적 에멀젼 조제물
TW200811082A (en) * 2006-04-27 2008-03-01 Teva Pharma Process for the preparation of cinacalcet base
ATE447546T1 (de) * 2006-04-27 2009-11-15 Teva Pharma Verfahren zur herstellung einer cinacalcetbase
PT2037936E (pt) 2006-06-21 2014-09-04 Opko Renal Llc Método de tratamento e prevenção do hiperparatiroidismo secundário
WO2008000422A1 (en) * 2006-06-27 2008-01-03 Sandoz Ag Amorphous form of cinacalcet
WO2008000423A1 (en) * 2006-06-27 2008-01-03 Sandoz Ag Crystalline form of cinacalcet
EP1914224A1 (de) * 2006-10-19 2008-04-23 Sandoz AG Amorphes Cinacalcethydrochlorid
GB0613674D0 (en) * 2006-07-10 2006-08-16 Proskelia Sas Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
WO2008027522A2 (en) * 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Solid composites of a calicum receptor-active compound
CN101547922B (zh) * 2006-10-04 2012-06-20 辉瑞产品公司 作为钙受体拮抗剂的吡啶并[4,3-d]嘧啶-4(3H)-酮衍生物
JP5470653B2 (ja) * 2006-10-26 2014-04-16 アムジエン・インコーポレーテツド カルシウム受容体調節剤
WO2008058236A2 (en) * 2006-11-08 2008-05-15 Dr. Reddy's Labortories, Ltd. Methods for preparing cinacalcet hydrochloride
US20080146845A1 (en) * 2006-11-20 2008-06-19 Boaz Gome Process for preparing Cinacalcet
CA2672560A1 (en) * 2006-12-15 2008-06-26 Ruprecht-Karls-Universitaet Heidelberg Methods for treating podocyte-related disorders
CA2681582C (en) 2007-03-30 2015-07-14 Amgen Inc. Methods of treating bowel disorders
CA2701638A1 (en) * 2007-04-02 2008-10-09 Concert Pharmaceuticals Inc. Pharmaceutical calcimimetics
US11752158B2 (en) 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
CN104523707B (zh) 2007-04-25 2022-08-26 欧普科Ip 控股Ii 有限公司 包含维生素d化合物和蜡质载体的口服控释组合物
WO2008139947A1 (ja) * 2007-05-08 2008-11-20 Ajinomoto Co., Inc. 下痢の予防又は治療剤
CA2691196C (en) * 2007-06-21 2016-05-24 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
ITMI20071261A1 (it) * 2007-06-22 2008-12-23 Dipharma Francis Srl Procedimento per la preparazione di cinacalcet
AU2008275595B2 (en) * 2007-07-10 2013-11-14 Amgen Inc. Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
WO2009025792A2 (en) * 2007-08-16 2009-02-26 Teva Pharmaceutical Industries Ltd. Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
AU2008328362A1 (en) * 2007-11-23 2009-05-28 Leo Pharma A/S Novel cyclic hydrocarbon compounds for the treatment of diseases
WO2009107660A1 (ja) 2008-02-25 2009-09-03 味の素株式会社 糖尿病又は肥満病の予防又は治療剤
JPWO2009107579A1 (ja) * 2008-02-25 2011-06-30 味の素株式会社 コク味付与剤
WO2009119554A1 (ja) * 2008-03-24 2009-10-01 味の素株式会社 消化管の重炭酸分泌促進剤
US8609655B2 (en) * 2008-03-28 2013-12-17 Amgen Inc. Calcimimetic compound for use in the treatment of epithelial injury
JP5533648B2 (ja) 2008-04-17 2014-06-25 味の素株式会社 免疫賦活剤
US8614354B2 (en) * 2008-06-18 2013-12-24 Erregierre S.P.A. Process for the synthesis of cinacalcet hydrochloride
US20110178326A1 (en) * 2008-08-06 2011-07-21 Actavis Group Ptc Ehf Unsaturated cinacalcet salts and processes for preparing cinacalcet hydrochloride
US9133140B2 (en) 2008-08-22 2015-09-15 Daiichi Sankyo Company, Limited Cycloalkylamne derivatives
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
US20110318417A1 (en) * 2008-12-08 2011-12-29 Actavis Group Ptc Ehf Highly pure cinacalcet or a pharmaceutically acceptable salt thereof
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
WO2010086129A1 (en) 2009-01-27 2010-08-05 Rathiopharm Gmbh Inclusion complex comprising cinacalcet and cyclodextrin
AU2010215520B2 (en) 2009-02-19 2016-07-21 F.I.S. - Fabbrica Italiana Sintetici S.P.A. Process for preparing Cinacalcet hydrochloride
CA2754209A1 (en) 2009-03-05 2010-09-10 Cipla Limited Process for the preparation of cinacalcet and salts thereof, and intermediates for use in the process
EP2406211B1 (de) 2009-03-09 2018-06-27 Megafine Pharma (P) Ltd. Neues verfahren zur herstellung von cinacalcet und neues zwischenprodukt davon
WO2010103429A1 (en) 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
WO2010118055A1 (en) * 2009-04-09 2010-10-14 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
WO2010128388A2 (en) 2009-05-08 2010-11-11 Aurobindo Pharma Limited An improved process for the preparation of intermediate compounds useful for the preparation of cinacalcet
WO2010136037A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
US8785494B2 (en) 2009-05-27 2014-07-22 Leo-Pharma A/S Calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010150837A1 (ja) * 2009-06-25 2010-12-29 第一三共株式会社 インドリン誘導体
EP2458983B1 (de) 2009-07-31 2015-07-08 Cognition Therapeutics, Inc. Hemmer des kognitiven abbaus
ES2445532T3 (es) 2009-09-10 2014-03-03 Zach System S.P.A. Proceso para preparar cinacalcet
US8759586B2 (en) 2009-09-16 2014-06-24 Ranbaxy Laboratories Limited Processes for the preparation of cinacalcet
MX338041B (es) 2009-09-25 2016-03-30 Oryzon Genomics Sa Inhibidores de demetilasa-1 especificos de lisina y su uso.
US8722732B2 (en) 2009-09-29 2014-05-13 Nektar Therapeutics Oligomer-calcimimetic conjugates and related compounds
WO2011056325A2 (en) 2009-09-29 2011-05-12 Nektar Therapeutics Oligomer-calcimimetic conjugates and related compounds
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
EP2314286A1 (de) 2009-10-21 2011-04-27 Ratiopharm GmbH Schmelzgranuliertes Cinacalcet
CN102119137A (zh) * 2009-11-02 2011-07-06 上海威智医药科技有限公司 盐酸西那卡塞的合成方法
IT1396623B1 (it) 2009-11-26 2012-12-14 Dipharma Francis Srl Procedimento per la preparazione di cinacalcet e suoi intermedi
US9186337B2 (en) 2010-02-24 2015-11-17 Oryzon Genomics S.A. Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
WO2011123476A1 (en) 2010-03-29 2011-10-06 Cytochroma Inc. Methods and compositions for reducing parathyroid levels
ES2607081T3 (es) 2010-04-19 2017-03-29 Oryzon Genomics, S.A. Inhibidores de desmetilasa específica de lisina-1 y su uso
WO2011146583A2 (en) 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
RU2599788C2 (ru) * 2010-06-30 2016-10-20 Лео Фарма А/С Новая полиморфная форма кальцимиметического соединения
EP2588445A1 (de) * 2010-06-30 2013-05-08 Leo Pharma A/S Neue polymorphe form einer calcimimetischen verbindung
US8921606B2 (en) * 2010-07-16 2014-12-30 Hetero Research Foundation Process for cinacalcet hydrochloride
EP2598480B1 (de) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylaminderivate als lsd1-hemmer
LT2598482T (lt) 2010-07-29 2018-07-10 Oryzon Genomics, S.A. Demetilazės lsd1 inhibitoriai arilciklopropilamino pagrindu ir jų medicininis panaudojimas
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
CN101993379B (zh) * 2010-10-22 2013-06-19 能特科技股份有限公司 一种盐酸西那卡塞的制备方法
US20130261132A1 (en) 2010-11-26 2013-10-03 Leo Pharma A/S Calcium-sensing receptor-active compounds
JP2014508104A (ja) 2010-11-26 2014-04-03 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
JP2014500882A (ja) 2010-11-26 2014-01-16 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
US20130245084A1 (en) 2010-11-26 2013-09-19 Leo Pharma A/S Calcium-sensing receptor-active compounds
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2651448B1 (de) 2010-12-13 2018-11-28 QuiaPEG Pharmaceuticals AB Wasserlösliche, nicht-peptidische, nicht-nukleotidischen phosphoramidatfunktionalisierte polymere
WO2012107498A1 (en) 2011-02-08 2012-08-16 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative disorders
BR112014009306B1 (pt) 2011-10-20 2021-07-20 Oryzon Genomics S.A. Compostos de (hetero)aril ciclopropilamina como inibidores de lsd1
CA2849564C (en) 2011-10-20 2020-10-20 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
CZ303627B6 (cs) 2011-11-25 2013-01-16 Zentiva, K.S. Zpusob výroby Cinacalcetu
CN103450027B (zh) 2012-05-29 2015-07-29 上海京新生物医药有限公司 盐酸西那卡塞的制备方法
CA2876315C (en) 2012-06-12 2021-05-25 Marek Kwiatkowski Conjugates of biologically active molecules to functionalized polymers
WO2014031755A1 (en) * 2012-08-21 2014-02-27 The Board Of Regents Of The University Of Texas System Fendiline derivatives and methods of use thereof
IN2015MN00421A (de) * 2012-08-27 2015-09-04 Lupin Ltd
FR2995307A1 (fr) 2012-09-07 2014-03-14 Prod Chim Auxiliaires Et De Synthese Procede de preparation du cinacalcet et de ses sels pharmaceutiquement acceptables
PL2730279T3 (pl) 2012-11-09 2015-12-31 K H S Pharma Holding Gmbh Preparaty cynakalcetu o natychmiastowym uwalnianiu
WO2014096277A1 (en) 2012-12-21 2014-06-26 Synthon B.V. Tablet composition comprising cinacalcet hydrochloride
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
CA2915432C (en) 2013-06-26 2019-03-05 Jubilant Life Sciences Limited Disintegrant free composition of cinacalcet
EP4023294A1 (de) 2014-01-31 2022-07-06 Cognition Therapeutics, Inc. Isoindolinzusammensetzungen und verfahren zur behandlung der alzheimer-krankheit
EP3148972B1 (de) 2014-05-27 2019-08-21 Cardioxyl Pharmaceuticals, Inc. Pyrazolonderivate als nitroxyldonatoren
CN104045568A (zh) * 2014-06-18 2014-09-17 中山奕安泰医药科技有限公司 一种合成(r)-1–(萘-1-基)乙胺的新工艺
CR20170085A (es) 2014-08-07 2017-04-25 Opko Ireland Global Holdings Ltd Terapia adjuntiva con 25-hidroxi vitamina d
CN104478736B (zh) * 2014-12-16 2016-07-13 成都启泰医药技术有限公司 一种盐酸西那卡塞的制备方法
US20180155270A1 (en) 2015-05-29 2018-06-07 Lupin Limited Process for preparation of cinacalcet intermediate and cinacalcet hydrochloride
KR20180123100A (ko) 2016-03-28 2018-11-14 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법
EP4011396A1 (de) 2017-03-10 2022-06-15 QuiaPEG Pharmaceuticals AB Lösbare konjugate
BR112019023851A2 (pt) 2017-05-15 2020-08-18 Cognition Therapeutics, Inc. compostos, suas composições farmacêuticas e métodos para tratamento de doenças neurodegenerativas
JP2021535920A (ja) 2018-09-12 2021-12-23 キアペグ ファーマシューティカルズ アクチエボラグ 放出可能なｇｌｐ−１コンジュゲート
CN111196759B (zh) * 2018-11-16 2023-03-24 上海博志研新药物技术有限公司 盐酸西那卡塞及其中间体的制备方法
MX2022002282A (es) * 2019-08-28 2022-03-25 Unilever Ip Holdings B V Compuestos novedosos para aclarar la piel.
WO2021191417A1 (en) 2020-03-27 2021-09-30 Som Innovation Biotech, S.A. Compounds for use in the treatment of synucleinopathies
RU2739376C1 (ru) * 2020-07-24 2020-12-23 Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) Способ получения фендилина

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2276618A (en) 1942-03-17 N-phenylaliphatic bihxdroxithenyl-
US2930731A (en) 1952-04-08 1960-03-29 Upjohn Co Bis[beta-(ortho-hydrocarbonoxyphenyl)iso-propyl]amines
BE570596A (de) 1957-08-26
BE621300A (de) 1961-08-14
US3262977A (en) 1962-03-10 1966-07-26 Chinoin Gyogyszer Es Vegyeszet N-aralkyl-1, 1-diphenyl-propylamine derivatives
NL293886A (de) 1962-06-19 1965-04-12 Merck Ag E
US3318952A (en) * 1964-01-22 1967-05-09 Sandoz Ag Dibenzylsulfamides
US3459767A (en) 1965-08-10 1969-08-05 Pfizer & Co C Aminomethylindoles
GB1109924A (en) 1965-11-29 1968-04-18 Roche Products Ltd Novel substituted diphenylalkyl amines and a process for the manufacture thereof
DE1618005A1 (de) 1966-09-22 1971-09-09 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen Amino-dihalogen-phenyl-aethylaminen
CH480791A (de) 1967-01-17 1969-11-15 Ciba Geigy Schädlingsbekämpfungsmittel
GB1263987A (en) 1969-05-30 1972-02-16 Allen & Hanburys Ltd Phenethylamine derivatives
US4129598A (en) * 1972-05-31 1978-12-12 Synthelabo Phenylethylamine derivatives
GB1448437A (en) 1973-02-24 1976-09-08 Beecham Group Ltd Diphenylpropylamines
US3862925A (en) 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US4000197A (en) * 1973-07-23 1976-12-28 The University Of Iowa Research Foundation Asymmetric synthesis of phenylisopropylamines
US3842067A (en) 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (de) 1974-03-08 1982-06-04
US4014937A (en) 1974-08-26 1977-03-29 Pfizer Inc. 3,4-And 3,5-dialkoxyphenethylamines
HU169507B (de) * 1974-09-25 1976-12-28
US3987201A (en) 1974-12-24 1976-10-19 Eli Lilly And Company Method for treating arrhythmia
US4105602A (en) 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
JPS5390272A (en) 1977-01-13 1978-08-08 Sendai Fukusokan Kagaku Kenkiy Method of producing optically active salsolizine
US4608391A (en) 1977-07-05 1986-08-26 Cornell Research Foundation Inc. Catecholamine derivatives, a process for their preparation and pharmaceutical compositions thereof
US4289787A (en) 1977-12-19 1981-09-15 Eli Lilly And Company Quaternary ammonium antiarrhythmic drugs
DD144050A5 (de) 1978-06-05 1980-09-24 Ciba Geigy Ag Verfahren zur herstellung von n-alkylierten aminoalkoholen
DE2825961A1 (de) 1978-06-14 1980-01-03 Basf Ag Fungizide amine
CA1142954A (en) 1978-07-03 1983-03-15 Jack Mills Phenethanolamines, compositions containing the same, and method for effecting weight control
US4391826A (en) 1978-07-03 1983-07-05 Eli Lilly And Company Phenethanolamines, compositions containing the same, and method for effecting weight control
ZA794872B (en) 1978-09-20 1980-11-26 Schering Corp A phenylalkylaminoethylsalicylamide,its preparation and pharmaceutical compositions containing it
FR2436773A1 (fr) 1978-09-22 1980-04-18 Roussel Uclaf Nouveaux derives du 3-(aminoethyl) phenol et leurs sels, procede de preparation et application a titre de medicaments
DE2841184C2 (de) * 1978-09-22 1986-09-25 Hochtemperatur-Reaktorbau GmbH, 4600 Dortmund Vorrichtung zur Durchmischung der Heißgassträhnen bei einem gasgekühlten Hochtemperaturreaktor
US4360511A (en) 1978-11-29 1982-11-23 Medi-Physics, Inc. Amines useful as brain imaging agents
DD150456A5 (de) 1979-03-01 1981-09-02 Ciba Geigy Ag Verfahren zur herstellung von derivaten des 3-amino-1,2-propandiols
EP0023385B1 (de) 1979-06-16 1982-12-15 Beecham Group Plc Äthanamin-Derivate, ihre Herstellung und Verwendung in pharmazeutischen Zusammensetzungen
JPS603387B2 (ja) 1980-07-10 1985-01-28 住友化学工業株式会社 新規光学活性イミダゾリジン−２−オン誘導体およびその製法
HU183430B (en) 1981-05-12 1984-05-28 Chinoin Gyogyszer Es Vegyeszet Process for producing cyclodextrine inclusion complexes of n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine or n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine-hydrochloride
US4591605A (en) 1981-11-10 1986-05-27 Research Foundation Of State University Of New York Method and ingestible formulation for inhibiting the secretion of stomach acid
US4658060A (en) 1982-04-26 1987-04-14 Schering Corporation Preparation of (-)-5-(beta)-1-hydroxy-2-((beta)-1-methyl-3-phenylpropyl)aminoethyl) salicylamide
DE3225879A1 (de) 1982-07-10 1984-01-12 Basf Ag, 6700 Ludwigshafen Trans-3-(4'-tert.-butylcyclohexyl-1')-2-methyl-1-dialkyl-aminopropane, ihre herstellung und verwendung als arzneimittel
CA1258454A (en) 1982-08-10 1989-08-15 Leo Alig Phenethanolamines
US4647446A (en) 1982-08-18 1987-03-03 The Regents Of The University Of California Rapid brain scanning radiopharmaceutical
JPS5950358A (ja) 1982-09-14 1984-03-23 Sumitomo Chem Co Ltd 光学活性なカルボン酸をグラフトしたクロマトグラフ充填剤およびそれを用いる鏡像体混合物の分離法
US4677101A (en) 1983-09-26 1987-06-30 Merck & Co., Inc. Substituted dihydroazepines useful as calcium channel blockers
US4661635A (en) 1983-11-21 1987-04-28 Mcneilab, Inc. Aralykyl (arylethynyl)aralkyl amines and their use as vasodilators and antihypertensives
DE3405333A1 (de) * 1984-02-15 1985-08-22 Sandoz-Patent-GmbH, 7850 Lörrach Neue allylamine, verfahren zu ihrer herstellung und ihre verwendung
US5334628A (en) 1984-06-09 1994-08-02 Kaken Pharmaceutical Co., Ltd. Amine derivatives, processes for preparing the same and fungicides containing the same
US4587253A (en) 1984-07-30 1986-05-06 Merck & Co., Inc. Bridged pyridine compounds useful as calcium channel blockers and analgesics
US4609494A (en) 1985-02-21 1986-09-02 Merck & Co., Inc. 5-acetyl-3,4,5,6-tetrahydro-4-oxo-2,6-methano-2H-1,3,5-benzothiazocine(benzodiazocine)-11-carboxylates useful as calcium channel blockers
US4839369A (en) 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
GB8522186D0 (en) 1985-09-06 1985-10-09 Erba Farmitalia Cycloalkyl-substituted 4-aminophenyl derivatives
DE3541181A1 (de) 1985-11-21 1987-05-27 Basf Ag Propylamine, verfahren zu ihrer herstellung und ihre verwendung als fungizide
US4675321A (en) 1986-02-07 1987-06-23 Merck & Co., Inc. Substituted pyrimidines useful as calcium channel blockers
US5034514A (en) 1986-03-17 1991-07-23 Cetus Corporation Novel cross-linking agents
US5030576A (en) 1986-04-30 1991-07-09 Genentech, Inc. Receptors for efficient determination of ligands and their antagonists or agonists
US4808718A (en) 1986-05-06 1989-02-28 Merck & Co., Inc. Fused polycyclic and bridged compounds useful as calcium channel blockers
HU200591B (en) 1986-07-11 1990-07-28 Chinoin Gyogyszer Es Vegyeszet Process for producing new diphenyl propylamine derivatives and pharmaceutical compositions comprising such compounds
US4797411A (en) 1986-07-18 1989-01-10 Farmitalia Carlo Erba S.P.A. Cycloalkyl-substituted 4-pyridyl derivatives and use as aromatase inhibitors
HU207280B (en) 1986-09-25 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing new phenyl-alkyl-amines and pharmaceutical compositions containing them
US5064657A (en) 1986-10-20 1991-11-12 University Of Utah Spider toxins and methods for their use as blockers of amino acid receptor function
US4925664A (en) 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
DE3782010T2 (de) 1986-12-04 1993-02-18 Toyo Jozo Kk Vom calcitonin-gen abgeleitete peptidderivate.
GB8720115D0 (en) 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
GB8709871D0 (en) 1987-04-27 1987-06-03 Turner R C Peptides
US4916145A (en) 1987-07-10 1990-04-10 Hoffmann-La Roche Inc. Substituted n-[(pyridyl)alkyl]aryl-carboxamide
EP0348490B1 (de) 1988-01-11 1995-09-27 Amylin Pharmaceuticals, Inc. Behandlung von diabetes mellitus typ 2
US5001251A (en) 1988-01-15 1991-03-19 E. R. Squibb & Sons, Inc. Optical resolution of DL-3-acylthio-2-methylpropanoic acid
AU3548089A (en) 1988-04-04 1989-11-03 Salk Institute Biotechnology/Industrial Associates, Inc., The Calcium channel compositions and methods
US5082837A (en) 1988-06-28 1992-01-21 Merrell Dow Pharmaceuticals Lactamimides as calcium antagonists
US4925873A (en) 1988-09-01 1990-05-15 E. R. Squibb & Sons, Inc. Method of treating skin injuries using thromboxane A2 receptor antagonists
JPH02200658A (ja) 1989-01-28 1990-08-08 Kumiai Chem Ind Co Ltd Ｎ―（置換）ベンジルカルボン酸アミド誘導体及び除草剤
RU2005717C1 (ru) * 1989-02-17 1994-01-15 Такеда кемикал-индастриз Лтд Способ получения производных аралкиламинов или их кислотно-аддитивных солей
US5011834A (en) 1989-04-14 1991-04-30 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon PCP receptor ligands and the use thereof
DD298412A5 (de) 1989-04-28 1992-02-20 ������@���Kk�� Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele
AU5957390A (en) 1989-07-03 1991-02-06 New York University Use of polyamines as ionic-channel regulating agents
GB8915712D0 (en) 1989-07-08 1989-08-31 Macintyre Iain Medical treatment
US5021599A (en) 1989-08-31 1991-06-04 Serpentix Conveyor Corporation Redox-responsive anion receptors
US5053337A (en) 1989-10-30 1991-10-01 Neurogenetic Corporation DNA encoding an α2B -adrenergic receptor
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
JP2818958B2 (ja) 1990-02-23 1998-10-30 塩野義製薬株式会社 ４―（４―アルコキシフェニル）―２―ブチルアミン誘導体およびその製造法
US5096908A (en) 1990-05-04 1992-03-17 Eli Lilly And Company Method of inhibiting gastric acid secretion
WO1992007829A1 (en) 1990-11-02 1992-05-14 The Upjohn Company Indole-3-methanamines useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents
JPH06506455A (ja) 1991-02-08 1994-07-21 ケンブリッジ・ニューロサイエンス・インコーポレイテッド 神経伝達物質放出調節剤としてのグアニジン置換体及びその誘導体ならびに神経伝達物質放出遮断物質を同定するための新規な方法
US5312928A (en) 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification
DE69206306T2 (de) * 1991-04-08 1996-06-13 Sumitomo Chemical Co Optisch aktive Sekundär-Aminverbindung, Verfahren zur Herstellung einer optisch aktiven Sekundär-Aminverbindung und Verfahren zur Herstellung optisch aktiver Carbonsäure durch die Verwendung dieser Verbindung.
US5688938A (en) 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
JP2728564B2 (ja) * 1991-08-23 1998-03-18 エヌピーエス・ファーマシウティカルズ・インコーポレイテッド カルシウム受容体活性化分子
US5763569A (en) 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
CA2173747C (en) 1991-08-23 2006-05-23 Edward F. Nemeth Calcium receptor-active arylalkyl amines
ATE161821T1 (de) 1991-11-12 1998-01-15 Pfizer Azyklische ethylendiaminderivate als 'substance p rezeptor' antagonisten
DE69217992T2 (de) 1991-12-30 1997-06-12 Janssen Pharmaceutica Nv Alpha-substituierte benzenmethanamin-derivate
AU3588693A (en) 1992-01-29 1993-09-01 Smithkline Beecham Corporation N-benzyloxamic acid, oxamate, and oxamide derivatives and their use as TNF and PDE IV inhibitors
JP3175339B2 (ja) * 1992-10-07 2001-06-11 住友化学工業株式会社 光学活性アミン化合物、その製法、その中間体及びその用途
RU2146132C1 (ru) 1993-02-23 2000-03-10 Брихэм энд Уимен З Хоспитал, Инк. Фармацевтическая композиция, активная в отношении рецептора кальция, способ лечения пациента, способ анализа соединения оказывать влияние на активность рецептора неорганического иона, нуклеиновая кислота, кодирующая рецептор, рецептор кальция
GB9326403D0 (en) 1993-12-24 1994-02-23 Oxford Asymmetry Ltd Improvements in or relating to chiral syntheses
US5631401A (en) * 1994-02-09 1997-05-20 Abbott Laboratories Inhibitors of protein farnesyltransferase and squalene synthase
EP1275635A1 (de) * 1994-10-21 2003-01-15 Nps Pharmaceuticals, Inc. Kalzium-Rezeptor aktive Verbindungen
US7043457B1 (en) 2000-06-28 2006-05-09 Probuild, Inc. System and method for managing and evaluating network commodities purchasing
US20060283332A1 (en) 2001-12-11 2006-12-21 Garman Michael H Hot beverage maker
US8526300B2 (en) 2008-03-31 2013-09-03 Ericsson Ab Method and apparatus for providing resiliency in multicast networks
KR101411428B1 (ko) 2012-07-12 2014-06-24 한국과학기술원 집광식 휴대용 형광 검출 시스템

Also Published As

Publication number Publication date
JP2007204482A (ja) 2007-08-16
HU229474B1 (en) 2014-01-28
ATE287390T1 (de) 2005-02-15
TW568896B (en) 2004-01-01
HK1020041A1 (en) 2000-03-10
DK1203761T3 (da) 2005-04-11
FR05C0029I1 (de) 2005-08-12
NL300199I2 (nl) 2005-10-03
BRPI9509411B8 (pt) 2021-07-06
EP1275635A1 (de) 2003-01-15
ES2285707T3 (es) 2007-11-16
FR05C0029I2 (fr) 2006-12-29
CN1312116C (zh) 2007-04-25
WO1996012697A9 (en) 2000-08-24
DE69533948T2 (de) 2005-12-15
NZ297157A (en) 1999-08-30
HK1052685A1 (zh) 2003-09-26
PT1203761E (pt) 2005-04-29
KR100403094B1 (ko) 2003-11-13
CZ292709B6 (cs) 2003-11-12
ATE359259T1 (de) 2007-05-15
JP4353985B2 (ja) 2009-10-28
WO1996012697A3 (en) 1996-06-13
CZ290670B6 (cs) 2002-09-11
CN1147459C (zh) 2004-04-28
CA2202879C (en) 2005-08-30
CN1534016A (zh) 2004-10-06
EP0787122B9 (de) 2007-10-17
HUT77980A (hu) 1999-02-01
DE69535461T2 (de) 2008-09-25
LU91182I2 (fr) 2006-07-11
HU0700718D0 (en) 2008-12-29
EP1203761A3 (de) 2002-05-15
LU91182I9 (de) 2019-01-07
TW200402407A (en) 2004-02-16
CZ118297A3 (en) 1997-09-17
JPH11130737A (ja) 1999-05-18
NL300199I1 (nl) 2005-08-01
EP0787122B1 (de) 2007-04-11
EP0787122A2 (de) 1997-08-06
CN1220658A (zh) 1999-06-23
DE69533948D1 (de) 2005-02-24
HK1046900B (zh) 2005-07-29
DE122005000033I1 (de) 2005-09-29
JP2882882B2 (ja) 1999-04-12
AU4195796A (en) 1996-05-15
JP4002338B2 (ja) 2007-10-31
JPH10513436A (ja) 1998-12-22
HK1002454A1 (en) 1998-08-28
UA55374C2 (uk) 2003-04-15
BRPI9509411B1 (pt) 2016-12-06
EP1203761A2 (de) 2002-05-08
ES2234768T3 (es) 2005-07-01
DE69535461D1 (de) 2007-05-24
WO1996012697A2 (en) 1996-05-02
BRPI9509411A (pt) 1997-12-30
RU2195446C2 (ru) 2002-12-27
HK1046900A1 (en) 2003-01-30
PL183499B1 (pl) 2002-06-28
EP1203761B1 (de) 2005-01-19
US6211244B1 (en) 2001-04-03
CA2202879A1 (en) 1996-05-02
HU228150B1 (en) 2012-12-28
AU709303B2 (en) 1999-08-26
PL319812A1 (en) 1997-09-01
KR100293621B1 (ko) 2001-11-26
EP1553078A1 (de) 2005-07-13

Similar Documents

Publication Publication Date Title
DE69535461D1 (de) Kalzium-rezeptor aktive verbindungen
ES2110421T3 (es) O-bencil-oximeteres y los agentes protectores de las plantas que contienen estos compuestos.
DE69216501D1 (de) Turbinenschaufel mit Innenkühlungskanal
DE3683175D1 (de) Azolylmethyloxirane - ihre herstellung und verwendung als pflanzenschutzmittel.
SE8402188L (sv) Fenetanolaminderivat
MX9206746A (es) Derivados de bifenilo, procedimiento para su preparacion y composicion farmaceutica que los contiene
FI930852A (fi) Foerledning foer bildande av ett roekgas ledande skorstensinnefoer av en husskorsten som behoever sanering, foerfarande foer framstaellning av en roerledning och anvaendning av densamma
NO953292L (no) Farnesyl:proteintransferaseinhibitorer som anticancermidler
ES2097274T3 (es) Composiciones polimericas autoextinguibles.
FI921408A (fi) Foerfarande foer skjutning av en borrstaong in i ett utslagshaol av en schaktugn, borrmaskin och duppelriktad klaemma
BE797911A (en) N-azoheterocyclic ureas - cns depressants, tranquillisers, muscle relaxants and anticonvulsants
FI915981A0 (fi) Tejpupplindningspultrusionsprocess foer framstaellning profiler av foerstaerkningsplast och foerstaerknings- plastprofil som framstaellts med foerfarandet.
FI1249U1 (fi) Maetapparat foer effekt och energi som oeverfoerts av ett elastiskt effekttransmissionsorgan saosom kedja, lina, vajer eller olika remmar
FI895361A0 (fi) Foerfaringssaett foer uppvaermning av ett taelt eller dylikt med hjaelp av en kamin och kamin foer utfoerande av foerfaringssaettet.
FI914791A0 (fi) Foerfarande foer istaondsaettning av spaerrytan av ett mellanstycke och en anordning i enlighet med foerfarandet.
FI911240A0 (fi) Faestningsyta foer ett gasmunsstycke i en svetsningsbraennare och foerfarande foer tillverkning daerav.
CS743087A2 (en) Herbicide and method of its effective substances production